IFM Investors Pty Ltd Raises Stake in DexCom, Inc. (NASDAQ:DXCM)

IFM Investors Pty Ltd lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 80,794 shares of the medical device company’s stock after buying an additional 415 shares during the period. IFM Investors Pty Ltd’s holdings in DexCom were worth $5,416,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Canada Pension Plan Investment Board lifted its position in DexCom by 189.1% during the second quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock worth $75,471,000 after buying an additional 435,401 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of DexCom by 16.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after acquiring an additional 353,019 shares during the last quarter. Bellevue Group AG lifted its holdings in shares of DexCom by 33.5% during the 1st quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company’s stock worth $169,380,000 after acquiring an additional 306,604 shares during the period. Magnetar Financial LLC purchased a new position in shares of DexCom during the 2nd quarter worth about $31,793,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of DexCom by 41.3% in the second quarter. Dimensional Fund Advisors LP now owns 919,650 shares of the medical device company’s stock worth $104,282,000 after acquiring an additional 268,802 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Performance

Shares of DXCM stock opened at $73.44 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The company’s fifty day moving average price is $70.11 and its two-hundred day moving average price is $98.24. The firm has a market capitalization of $29.21 billion, a P/E ratio of 47.38, a P/E/G ratio of 2.16 and a beta of 1.18. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 24th. The medical device company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.43 by $0.02. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $994.20 million for the quarter, compared to analysts’ expectations of $991.55 million. On average, research analysts anticipate that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the sale, the executive vice president now owns 66,249 shares in the company, valued at $4,607,617.95. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,824 shares of company stock worth $126,390 in the last ninety days. 0.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on DXCM. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. Stifel Nicolaus increased their target price on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Robert W. Baird lifted their target price on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, August 5th. Raymond James dropped their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $145.00 price objective on shares of DexCom in a research note on Tuesday, July 23rd. Six research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.